Liver Disease Diagnostics Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

How Are the key drivers contributing to the expansion of the liver disease diagnostics market?
The surge in alcohol intake is anticipated to drive the expansion of the liver disease diagnostics market in the future. A rise in alcohol use, attributed to changes in societal norms, enhanced affordability, widespread accessibility, and escalating stress or mental health complications, is contributing to this trend. Liver disease diagnostics are instrumental in understanding the alcohol's effect on liver health and in identifying early indicators of liver damage such as fatty liver, hepatitis, or cirrhosis. For example, in December 2022, a report by the National Health Service, a government department based in England, revealed that the proportion of alcohol consumers in the last year increased with age, commencing at 62% for individuals aged 16 to 24 and peaking at 85% for those 55 to 74 years old. Thus, this upsurge in alcohol intake is catalyzing the proliferation of the liver disease diagnostics market.

Get Your Liver Disease Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/liver-disease-diagnostics-global-market-report

What growth opportunities are expected to drive the liver disease diagnostics market's CAGR through 2034?
In recent times, the market for liver disease diagnostics has seen robust growth. From standing at $36.26 billion in 2024, it is projected to expand to $39.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors influencing this growth during the historical term include increasing frequency of both acute and chronic liver disorders, uptick in the prevalence of liver diseases, a surge in alcohol consumption, heightened consciousness about liver health, and a burgeoning healthcare infrastructure.

The market for liver disease diagnostics is predicted to experience substantial expansion in the forthcoming years, reaching a market size of $52.04 billion by 2029 with an annual compound growth of 7.4%. This growth over the projected period can be credited to factors such as the increasing elderly population, heightened investment in research and development, a rise in the frequency of biopsy procedures and illnesses, along with a growing acceptance of telemedicine. Key trends expected during this forecast period encompass the emergence of bespoke medicine, innovation in diagnostic kits, advancements in quick testing provisions, progress in healthcare sector technology and improvement in diagnostic methodologies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20862&type=smp

What are the emerging trends shaping the future of the liver disease diagnostics market?
Leading firms in the liver disease diagnostics market are concentrating on the innovation of novel solutions such as non-invasive tools for liver assessment, with the aim of creating more precise and efficient diagnostic methodologies. Non-invasive tools for liver assessment means diagnostic procedures that examine liver conditions using methods such as elastography or blood tests, eliminating the necessity for invasive procedures such as biopsies. For example, in September 2024, City Imaging & Clinical, a diagnostic center based in India, introduced FibroScan, a non-invasive diagnostic instrument for liver assessment. This was created to allow for early detection of liver diseases like non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). This state-of-the-art technology facilitates fast and precise assessments of liver stiffness and fat content, eliminating the necessity for invasive procedures such as biopsies. The process is quick, typically taking between 5 to 15 minutes, and involves positioning a probe on the skin over the liver. This probe generates sound waves that quantify liver tissue stiffness, allowing for the evaluation of fibrosis or scarring.

Which growth-oriented segments of the liver disease diagnostics market are leading the industry's development?
The liver disease diagnostics market covered in this report is segmented -

1) By Diagnosis Technique: Laboratory Tests, Imaging, Endoscopy, Biopsy, Other Diagnosis Techniques
2) By Disease: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Fibrosis, Cirrhosis, Hepatocellular Carcinoma, Other Diseases
3) By End Users: Hospitals, Laboratories, Other End Users

Subsegments:
1) By Laboratory Tests: Blood Tests (Liver Function Tests, Hepatitis Panel), Enzyme Tests (ALT, AST, ALP), Genetic Testing, Serological Tests
2) By Imaging: Ultrasound Imaging, CT Scans, MRI, Elastography (FibroScan)
3) By Endoscopy: Esophagogastroduodenoscopy (EGD), Capsule Endoscopy
4) By Biopsy: Liver Biopsy (Needle Biopsy), Fine Needle Aspiration Biopsy, Laparoscopic Biopsy
5) By Other Diagnosis Techniques: Molecular Imaging, Biomarker Testing, Fibrosis Scoring Systems

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20862

What regions are leading the charge in the liver disease diagnostics market?
North America was the largest region in the liver disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the liver disease diagnostics market?
Major companies operating in the liver disease diagnostics market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, Echosens SA, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG, bioMérieux SA, Genentech Inc., Perspectum Diagnostics Ltd., Owlstone Medical Ltd., Enterome SA, Atlentis Therapeutics AG, 89bio Inc., Aligos Therapeutics Inc., BioPredictive SAS, Cosara Diagnostics Pvt. Ltd., Hepion Pharmaceuticals Inc., HEPQuant LLC, Aiforia Technologies Plc

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20862&type=smp

What Is Covered In The Liver Disease Diagnostics Global Market Report?

•Market Size Forecast: Examine the liver disease diagnostics market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the liver disease diagnostics market for a structured understanding.
•Key Players Overview: Analyze major players in the liver disease diagnostics market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the liver disease diagnostics market.
•Segment Contributions: Evaluate how different segments drive overall growth in the liver disease diagnostics market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the liver disease diagnostics market.
•Industry Challenges: Identify potential risks and obstacles affecting the liver disease diagnostics market.
•Competitive Landscape: Review strategic developments in the liver disease diagnostics market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.